Epigenetische Wirkstoffentwicklung: Molekül Identifizierung und Optimierung, sowie Target Validierung (Z02)

• Subject Area: Biochemistry
• Term: from 2012 to 2024
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 192904750

The development of high-affinity inhibitors with potential application in clinical therapy involves a structured process of identifying target proteins and lead structures for inhibitory compounds. Such leads are then optimised in iterative rounds of chemical modification, structural analysis and functional assays. The Z02 core facility provides the CRC with the know-how and equipment to scale-up protein production, identify and validate suitable target proteins, obtain three-dimensional structures, find candidate compounds and optimise leads for ligand screening and protein crystallisation.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 992: Medical Epigenetics (MEDEP) - From Basic Mechanisms to Clinical Applications
• Applicant Institution: Albert-Ludwigs-Universität Freiburg
• Project Heads: Professor Dr. Bernhard Breit; Professor Dr. Oliver Einsle; Professor Dr. Stefan Günther